20599293

Source:http://linkedlifedata.com/resource/pubmed/id/20599293

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0030705, umls-concept:C0033860, umls-concept:C0034866, umls-concept:C0036043, umls-concept:C0043100, umls-concept:C0205081, umls-concept:C0205082, umls-concept:C1608841, umls-concept:C2699007
pubmed:issue	4
pubmed:dateCreated	2010-9-17
pubmed:abstractText	Patients with psoriasis tend to be overweight, and the efficacy of fixed-dose biologics may be compromised by high body weight.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7907132
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/ustekinumab
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	1097-6787
pubmed:author	pubmed-author:LangleyRichard GRG, pubmed-author:LebwohlMarkM, pubmed-author:LiShuS, pubmed-author:PappKim AKA, pubmed-author:ReichKristianK, pubmed-author:SzaparyPhilippeP, pubmed-author:WangYuhuaY, pubmed-author:YeildingNewmanN, pubmed-author:ZhuYaoweiY
pubmed:copyrightInfo	Copyright © 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
pubmed:issnType	Electronic
pubmed:volume	63
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	571-9
pubmed:dateRevised	2011-7-29
pubmed:meshHeading	pubmed-meshheading:20599293-Adult, pubmed-meshheading:20599293-Antibodies, Monoclonal, pubmed-meshheading:20599293-Body Mass Index, pubmed-meshheading:20599293-Body Weight, pubmed-meshheading:20599293-Cross-Over Studies, pubmed-meshheading:20599293-Dose-Response Relationship, Drug, pubmed-meshheading:20599293-Double-Blind Method, pubmed-meshheading:20599293-Drug Administration Schedule, pubmed-meshheading:20599293-Drug Toxicity, pubmed-meshheading:20599293-Female, pubmed-meshheading:20599293-Follow-Up Studies, pubmed-meshheading:20599293-Humans, pubmed-meshheading:20599293-Male, pubmed-meshheading:20599293-Maximum Tolerated Dose, pubmed-meshheading:20599293-Middle Aged, pubmed-meshheading:20599293-Psoriasis, pubmed-meshheading:20599293-Risk Assessment, pubmed-meshheading:20599293-Severity of Illness Index, pubmed-meshheading:20599293-Treatment Outcome
pubmed:year	2010
pubmed:articleTitle	Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations.
pubmed:affiliation	Mount Sinai School of Medicine, New York, New York 10029, USA. Lebwohl@aol.com
pubmed:publicationType	Journal Article, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III